Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Destiny Pharma Ltd
Destiny Pharma Ltd
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Counteracting counterfeits in the pharmaceutical supply chain
Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
Naobios successfully optimises Sumagen's HIV vaccine for industrial production
Naobios will now focus on developing processes for the cGMP manufacture of Sumagen's HIV-1 vaccine candidate
Enzene launches EnzeneX 2.0 technology for biologics at CPHI Milan 2024
New platform enables uninterrupted processing and significant cost reductions
New Berry bottle complements preservative-free eye treatment dispensing
Easy-squeeze ophthalmic bottle designed for use with Aptar Pharma’s dispenser
Domino makes it easier than ever for pharmaceutical manufacturers to explore individual dose serialisation
New enhancements to the K600G printing solution streamline integration and usability
Upcoming event
CPhI India
26–28 November 2024 | Online Conference & Networking | Delhi, India
See all
Related Content
Drug Delivery
Positive update on the development of new XF‐platform drug formulations
Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development
Destiny Pharma secures £1.6 million grant to fight microbial resistance
The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment
Nick Rodgers joins Destiny Pharma
Research & Development
Destiny Pharma announces research collaboration with Aston University
Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media
Destiny Pharma establishes Scientific Advisory Board
Pharmaceutical
Destiny Pharma appoints Neil Clark new CEO
Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients
Destiny Pharma receives US FDA QIDP designation for novel antibacterial product
Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now